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Key Questions
What is already known about this subject?
 ► Previous studies have reported varying prevalences 
of peripheral artery disease (PAD) in a population 
with coronary artery disease (CAD), ranging from 
8-42% depending on diagnostic method.
 ► It is important to identify atherosclerosis in vascular 
beds other than the coronary arteries, since mor-
tality rates increase with number of arterial beds 
affected.
What does this study add?
 ► In this nationwide observational study including 110 
976 patients with a myocardial infarction (MI), we 
found the prevalence of PAD to be 3.8%, far less 
than previously reported.
 ► Selected CAD patients with concomitant PAD had in-
creased mortality, reinfarction, stroke, heart failure 
and bleeding risks.
How might this impact on clinical practice?
 ► The findings in this study suggests a more interdis-
ciplinary approach when dealing with patients with 
poly-vascular disease.
 ► Individuals with known CAD may benefit from PAD 
screening for early disease detection.
AbstrAct
Aim To describe the population of patients with previously 
diagnosed peripheral artery disease (PAD) experiencing 
a myocardial infarction (MI) and to investigate 1-year 
major adverse cardiac events (MACE: all-cause mortality, 
reinfarction, stroke and heart failure hospitalisation) 
following MI.
Background MI patients with PAD constitute a high-risk 
population with adverse cardiac outcomes. Contemporary 
real-life data regarding the clinical characteristics of this 
patient population and clinical event rates following MI 
remain scarce.
Methods This observational study included all MI patients 
presenting with ST-elevation MI or non-ST-elevation MI 
between 01 January 2005 and 31 December 2014 with 
(n=4213) and without (n=106 763) a concurrent PAD 
diagnosis, identified in the nationwide Swedish Web-
system for Enhancement and Development of Evidence-
based care in Heart disease Evaluated According to 
Recommended Therapies registry and the National Patient 
Registry (PAD prevalence: 3.8%). Cox proportional hazard 
models were applied to compare the outcome between the 
two populations.
Results MI patients with PAD were older and more 
often burdened with comorbidities, such as diabetes, 
hypertension and previous MI. After adjustments, PAD was 
significantly associated with higher rates of MACE (HR 
1.35, 95% CI 1.27 to 1.44), mortality (HR 1.59, 95% CI 
1.43 to 1.76), reinfarction (HR 1.48, 95% CI 1.32 to 1.66), 
stroke (HR 1.27, 95% CI 1.05 to 1.53), heart failure (HR 
1.29, 95% CI 1.20 to 1.40) and bleeding (HR 1.26, 95% CI 
1.09 to 1.47) at 1 year.
Conclusion A concurrent PAD diagnosis was 
independently significantly associated with higher rates 
of adverse outcomes following MI in a nationwide real-life 
MI population. The low prevalence of PAD compared with 
previous studies suggests significant underdiagnosing. 
Future studies should investigate if PAD screening with 
ankle–brachial index may increase diagnosing and 
subsequently lead to improved treatment of polyvascular 
disease
IntRoduCtIon SuMMARy
Peripheral artery disease (PAD) and coronary 
artery disease (CAD) are clinical manifesta-
tions of atherosclerosis involving different 
vascular beds. It has been established that the 
more arterial beds affected by atherosclerosis 
the higher the risk of experiencing a cardi-
ovascular event, such as stroke, myocardial 
infarction (MI) or death due to cardiovas-
cular causes.1 Substantiating this, various 
studies have shown that MI patients with PAD 
are a high-risk population that experiences 
more adverse cardiac outcomes compared 
with MI patients without PAD.2–7 The concur-
rent prevalence of PAD in patients with MI 
is uncertain; several studies have reported 
conflicting numbers ranging from 8% to 
42% depending on diagnostic definition and 
methods.4 5 8 9
The interest in the role of PAD in patients 
with CAD has lately been rising. A major 
contributor has been the Cardiovascular 
Outcomes for People Using Anticoagulation 
Strategies (COMPASS) trial, which showed 
that low-dose rivaroxaban two times per day 
plus aspirin decreased major adverse cardiac 
events (MACE) compared with rivaroxaban 
or aspirin alone in patients with PAD.10
Nonetheless, contemporary real-life data 
from large samples regarding the clinical 
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characteristics of MI patients with PAD remain scarce. We 
aimed to describe the baseline and clinical characteris-
tics in the population of patients with PAD experiencing 
an MI, to analyse adverse outcomes following MI, and to 
investigate prescriptions of guideline-based secondary 
preventive medical therapies in this patient group using 
a nationwide contemporary population-based registry.
MetHodS
Study sample
This observational follow-up study included all patients 
presenting with an ST-segment elevation MI (STEMI) 
or non-STEMI (NSTEMI) between 01 January 2005 and 
31 December 2014 with and without a concurrent PAD 
diagnosis. The patients were identified and included 
from the Swedish Web-system for Enhancement and 
Development of Evidence-based care in Heart disease 
Evaluated According to Recommended Therapies 
registry (SWEDEHEART). PAD was defined as having 
an electronic healthcare record of ICD-codes (10th 
version: I70–73; ninth version: 440–443) before base-
line. In total, 4213 MI patients with a previous PAD 
diagnosis (prevalence: 3.8%) were compared with 106 
763 MI patients without a previous PAD diagnosis.
national registries
SWEDEHEART consists of several subregistries and the 
ones used in this study includes the Register of Infor-
mation and Knowledge About Swedish Heart Intensive 
Care Admissions, which has information from coronary 
care units throughout the country, and the Swedish 
Coronary Angiography and Angioplasty Registry11 that 
provides data from all catheterisation labs in Sweden. 
The merged SWEDEHEART registry simplifies the 
transferring of information between hospitals and 
avoids repeated entering of data in different registries 
as well as making high-quality data available for research 
purposes. The registry contains clinical information 
on all patients in Sweden who are treated at coronary 
care units, who undergo coronary angiography and 
percutaneous coronary interventions. Data include 
risk factors, past medical history, treatment during 
hospitalisation, discharge medications and final diag-
noses. SWEDEHEART can also be connected to other 
registries using the unique personal number given to 
all Swedish citizens. We linked SWEDEHEART with 
the National Population Register to assess vital status 
and date of death, and the National Patient Registry to 
ascertain PAD status and comorbidities through ICD-10 
diagnostic codes. The personal numbers are replaced 
by a serial number to ensure anonymity.11
endpoints
The primary endpoint was 1-year MACE defined as 
all-cause mortality, rehospitalisation for MI, hospitali-
sation for stroke and hospitalisation for heart failure. 
Secondary endpoints were individual components 
of the primary composite endpoint at 1 year and 
hospitalisation for major bleeding (fatal, cerebral or 
bleeding requiring surgery or transfusion, defined by 
ICD-9 (430, 431, 432, 578, 285B, 456A, 531A, 531C, 
531E, 531G, 532A, 532C, 532E, 532G, 533A, 533C, 
533E, 533G, 534A, 534C, 534E, 534G and 569D) and 
ICD-10 (I60, I61, I62, D629, I850, K226, K250, K252, 
K254, K256, K260, K262, K264, K266, K270, K272, K274, 
K276, K280, K282, K284, K286, K290, K625, K920, K921 
and K922) codes).
Statistical analysis
Continuous variables are expressed as means with SD 
and differences between groups were compared using 
Student’s t-test. Categorical variables are expressed 
as counts and percentages and differences between 
groups were analysed using the χ2 test. Endpoints in 
patients with and without PAD were calculated using 
the Kaplan-Meier survival estimator and log-rank tests 
were used to calculate the differences between the 
groups. For reinfarction, we used a 30-day blanking 
period post-discharge to avoid early follow-up visits 
misclassified as new MIs. HRs with 95% CIs were 
calculated using univariable and multivariable Cox 
proportional hazard models. Multivariable models 
were adjusted for potential confounders in three 
models. The first model adjusted for age and sex. The 
second model adjusted for age, sex and comorbidities 
including atrial fibrillation, CAD presentation (angio-
graphic findings and presenting symptoms), diabetes, 
smoking, hypertension, stroke, MI, previous percuta-
neous coronary intervention (PCI), previous coronary 
artery bypass graft (CABG), heart failure, renal failure, 
chronic obstructive pulmonary disease and previous 
bleeding. The final model adjusted for all of the above 
and additionally guideline-based medical therapy (dual 
antiplatelet therapy (DAPT), ACE inhibitor or angio-
tensin II receptor blocker (ACEi/ARB), beta-blockers 
and statins) as well as management with PCI and CABG 
and only included hospital survivors. The count and 
percentage of missing data were reported for each vari-
able. All p values were two-tailed and a value of <0.05 
was considered statistically significant. All analyses were 
performed using STATA V.14.0 and SPSS V.25.
ReSultS
Patient characteristics
Baseline characteristics for MI patients with and 
without PAD are outlined in table 1. The prevalence 
of PAD was 3.8% (4213/110 976). Patients with PAD 
were older (mean 73 vs 67 years, p<0.001), and had 
a heavier smoking history (more previous smokers 
and current smokers) (p<0.001). Moreover, a larger 
burden of comorbidities was seen in PAD patients, with 
higher prevalence’s of diabetes, hypertension, hyper-
lipidaemia, previous MI, previous stroke, heart failure, 
renal failure, chronic obstructive pulmonary disease 
and previous bleeding (all p<0.001).
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(n=110 976) Missing n (%) P value
n (%)








Sex n (%) 
  Male 2801 (66.5) 73 183 (68.6) 75 984 (68.5) 0 0.005 
  Female 1412 (33.5) 33 580 (31.5) 34 992 (31.5)
Smoking status n (%) 
  Never 978 (23.2) 41 055 (38.5) 42 033 (37.9) 5918 (5.3) <0.001 
  Ex-smoker 1825 (42.3) 33 653 (31.5) 35 478 (32.0)
 (>1 month) Smoker 1104 (26.2) 26 443 (24.8) 27 547 (24.8)
Diabetes n (%) 1584 (37.7) 22 077 (20.7) 23 664 (21.3) 0 <0.001
Hypertension n (%) 3543 (84.1) 59 561 (55.8) 63 104 (56.9) 1241 (1.2) <0.001
Hyperlipidaemia n (%) 2286 (54.3) 24 025 (22.5) 26 311 (23.7) 1141 (1.0) <0.001
Previous myocardial infarction n (%) 1791 (42.5) 17 072 (16.0) 18 863 (17.0) 1692 (1.6) <0.001
Previous PCI n (%) 617 (14.7) 6431 (6.0) 7048 (6.4) 162 (0.2) <0.001
Previous CABG n (%) 825 (19.6) 4940 (4.6) 5765 (5.2) 92 (0.1) <0.001
Previous stroke
n (%)
911 (21.6) 8360 (7.8) 9271 (8.4) 2930 (2.7) <0.001
Heart failure n (%) 786 (18.7) 4778 (4.5) 5564 (5.0) 0 <0.001
Renal failure n (%) 445 (10.6) 1596 (1.5) 2041 (1.8) 0 <0.001
Dialysis n (%) 124 (2.9) 356 (0.3) 480 (0.4) <0.001
COPD n (%) 617 (14.7) 5378 (5.0) 5995 (5.4) 0 <0.001
Previous bleeding n (%) 427 (10.1) 4053 (3.8) 4480 (4.0) 0 <0.001
CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; PAD, peripheral artery disease; 
PCI, percutaneous coronary intervention.
Clinical findings and presentation
The laboratory findings, clinical presentations, ECG 
changes and procedural characteristics during hospi-
talisation for MI patients with and without PAD are 
outlined in table 2. The laboratory findings showed 
that patients with MI and PAD had higher levels of 
C reactive protein and creatinine and lower levels of 
haemoglobin. Patients with PAD were more likely to 
present with dyspnoea compared with patients without 
PAD. They also had slightly lower blood pressure and 
higher heart rate compared with the non-PAD group 
at presentation. Moreover, the PAD group experienced 
more NSTEMI than STEMI, and their presenting ECG 
showed more atrial fibrillation or flutter and more 
bundle branch block. PAD patients had more severe 
CAD with more multivessel and left main disease on the 
angiogram and they had lower left ventricular function. 
The PAD group were less often revascularised with PCI 
or CABG compared with the non-PAD group. All differ-
ences presented have a p value of <0.05.
discharge medications
Patients with MI and PAD were less frequently 
discharged with DAPT as seen in table 3. In contrast, 
these patients were more often discharged with antico-
agulants, such as warfarin, as atrial fibrillation was more 
common. There were no clinically relevant differences 
in prescriptions of ACEi/ARB, beta-blockers or statins. 
MI and PAD patients more often received digoxin and 
diuretics.
Clinical endpoints
The primary endpoint of 1-year MACE occurred signif-
icantly more frequently in the PAD group compared 
with the non-PAD group with an unadjusted HR of 2.65 
(95% CI 2.52 to 2.78) (table 4 and figure 1). Following 
adjustment for age and sex, the HR decreased to 2.09 
(95% CI 1.98 to 2.20). Further adjustment for comor-
bidities decreased the HR to 1.31 (95% CI 1.21 to 1.42). 
Adjustments for guideline-based medical therapy and 
management with PCI and CABG increased the HR 
to 1.35 (95% CI 1.27 to 1.44). The adjusted secondary 
endpoints, mortality (HR 1.59, 95% CI 1.43 to 1.76), 
reinfarction (HR 1.48, 95% CI 1.32 to 1.66), stroke 
(HR 1.27, 95% CI 1.05 to 1.53), heart failure (HR 1.29, 
95% CI 1.20 to 1.40) and bleeding rates (HR 1.26, 95% 
CI 1.09 to 1.47), were significantly higher in the PAD 
population (table 4).
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Table 2 Laboratory findings, clinical presentation, ECG changes and procedures in the different MI groups during 
hospitalisation
PAD Non-PAD Entire population Missing n (%) P value
Creatinine mean (SD) 120.0 (106.0) 88.6 (47.0) 90.0 (50.8) 4878 (4.4) <0.001
Haemoglobin mean (SD) 132.6 (17.9) 140.7 (15.7) 140.4 (15.9) 16 228 (14.6) <0.001
CRP mean (SD) 28.4 (50.1) 18.0 (39.6) 18.3 (40.1) 13 362 (12.0) <0.001
Coronary marker levels mean (SD) 
  Troponin T 125.4 (852) 85.4 (675) 86.8 (682) 79 943 (72.0) 0.056
  Troponin I 23.5 (189) 21.5 (136) 21.6 (139) 68 354 (61.2) 0.571
Systolic blood pressure mean (SD) 145.3 (30.8) 148.4 (29.2) 148.3 (29.3) 5831 (5.3) <0.001
Diastolic blood pressure mean (SD) 80.6 (17.2) 85.25 (17.1) 85.3 (17.2) 8766 (7.9) <0.001
Heart rate mean (SD) 83.1 (24.3) 78.7 (21.6) 78.9 (21.7) 970 (0.9) <0.001
Presenting symptoms n (%) 
  Chest pain 3465 (82.3) 94 583 (88.6) 98 048 (88.4) 1203 (1.1) <0.001 
  Dyspnoea 378 (9.0) 4392 (4.1) 4770 (4.3)
  Cardiac arrest 58 (1.4) 1325 (1.2) 1383 (1.3)
  Other 277 (6.6) 5295 (5.0) 5572 (5.0)
Infarct type n (%) 
  STEMI 1261 (29.9) 43 505 (40.8) 44 766 (40.3) 396 (0.4) <0.001 
  NSTEMI 2940 (69.8) 62 874 (58.8) 65 814 (59.3)
ECG: ST-segment n (%) 
  Normal 676 (16.1) 22 161 (20.8) 22 837 (20.6) 12 915 (11.6) <0.001 
  ST-elevation 1193 (28.3) 41 644 (39.0) 42 837 (38.6)
  ST-depression 1259 (29.9) 20 743 (19.4) 22 002 (19.3)
  Pathological T-wave 384 (9.1) 10 001 (9.4) 10 385 (9.4)
ECG: rhythm n (%) 
  Sinus 3470 (82.4) 95 863 (89.8) 99 333 (89.5) 3740 (3.4) <0.001 
  Atrial fibrillation/flutter 545 (12.9) 7358 (6.9) 7903 (7.1)
ECG: QRS n (%) 
  Normal 2464 (58.5) 72 427 (67.8) 74 891 (67.5) 15 317 (13.8) <0.001 
  LBBB 315 (7.5) 4369 (4.1) 4684 (4.2)
  RBBB 227 (5.4) 4046 (3.8) 4273 (3.9)
  Pathological Q-wave 479 (11.4) 11 332 (10.6) 11 811 (10.6)
Left ventricular function n (%) 
  Normal≥50% 1454 (34.5) 50 705 (47.5) 52 159 (47.0) 22 778 (20.5) <0.001 
  Slightly decreased 40%–49% 780 (18.5) 18 770 (17.6) 19 550 (17.6)
  Moderately decreased 30%–39% 576 (13.7) 10 991 (10.3) 11 567 (10.4)
  Severely decreased <30% 350 (8.3) 4572 (4.3) 4922 (4.4)
  PCI n (%) 2846 (67.6) 82 397 (77.2) 85 243 (76.8) 0 <0.001
  CABG n (%) 280 (6.7) 4247 (4.9) 5527 (5.0) 0 <0.001
Angiographic findings 
  Normal/atheromatosis 208 (4.9) 9708 (9.1) 9916 (8.9) 646 (0.6) <0.001 
  1-vessel, no LMD 919 (21.8) 42 138 (39.5) 43 057 (38.8)
  2-vessel, no LMD 970 (23.0) 26 096 (24.4) 27 066 (24.4)
  3-vessel, no LMD 1311 (31.1) 20 608 (19.3) 21 919 (19.8)
  LMD 756 (17.9) 7616 (7.1) 8372 (7.5)
CABG, coronary artery bypass graft; CRP, C reactive protein;LBBB, left bundle branch block; LMD, left main disease; MI, myocardial 
infarction; NSTEMI, non-ST-segment elevation MI;PAD, peripheral artery disease; PCI, percutaneous coronary intervention;RBBB, right 
bundle branch block; STEMI, ST-segment elevation MI.
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Table 3 Discharge medications (only hospital survivors)
PAD Non-PAD Entire population Missing n (%) P value
DAPT n (%) 3050 (77.2) 87 052 (83.9) 90 102 (83.7) 294 (0.3) <0.001
Aspirin n (%) 3686 (93.3) 99 068 (93.3) 102 754 (95.4) 134 (0.1) <0.001
P2Y12 inhibitor n (%) types 3223 (81.5) 89 907 (86.7) 93 130 (86.5) 160 (0.2) <0.001
  Clopidogrel 2696 (68.2) 71 170 (68.6) 73 866 (68.6)
  Prasugrel 30 (0.8) 1612 (1.6) 1642 (1.5)
  Ticagrelor 473 (12.0) 16 609 (16.0) 17 082 (15.9)
Anticoagulants n (%)
types
369 (9.3) 3777 (3.6) 4146 (3.9) 725 (0.7) <0.001
  Warfarin 366 (9.3) 3700 (3.6) 4066 (3.8)
  Dabigatran 2 (0.05) 46 (0.04) 48 (0.04)
  Rivaroxaban 1 (0.03) 14 (0.01) 15 (0.01)
ACEi/ARB n (%) 3044 (77.0) 78 897 (76.1) 81 942 (76.1) 1465 (1.4) 0.172
Beta blockers n (%) 3531 (89.3) 93 873 (90.5) 97 404 (90.5) 149 (0.1) 0.022
Calcium antagonists n (%) 1073 (27.1) 13 797 (13.3) 14 870 (13.8) 170 (0.2) <0.001
Digitalis n (%) 151 (3.8) 1852 (1.8) 2003 (1.9) 151 (0.1) <0.001
Diuretics n (%) 1791 (45.3) 23 446 (22.6) 25 237 (23.4) 159 (0.2) <0.001
Statins n (%) 3556 (90.0) 96 649 (93.2) 100 205 (93.1) 161 (0.2) <0.001
Other lipid lowering agents
n (%) types
122 (3.1) 1289 (1.2) 1411 (1.3) 1193 (1.1) <0.001
  Ezetimibe 95 (2.4) 978 (0.9) 1073 (1.0)
  Fibrates 13 (0.3) 156 (0.2) 169 (0.2)
ACEi, ACE inhibitor; ARB, angiotensin II receptor blocker; DAPT, dual antiplatelet therapy (aspirin and P2Y12 inhibitor);PAD, peripheral artery 
disease.
Table 4 Clinical endpoints for MI patients with PAD compared with non-PAD patients at 1 year
End points
Kaplan-Meier event rates (%) Unadjusted HR 
(95% CI)
Adjusted HR (95% CI)
PAD Non-PAD Model 1 Model 2 Model 3
MACE 0.647 (35.3) 0.852 (14.8) 2.65 (2.52 to 2.78)* 2.09 (1.98 to 2.20)* 1.31 (1.21 to 1.42)* 1.35 (1.27 to 1.44)*
Mortality 0.807 (19.3) 0.934 (6.6) 3.24 (3.00 to 3.50)* 2.38 (2.21 to 2.57)* 1.69 (1.48 to 1.91)* 1.59 (1.43 to 1.76)*
Reinfarction 0.893 (10.7) 0.959 (4.1) 2.65 (2.39 to 2.94)* 2.24 (2.02 to 2.49)* 1.23 (1.05 to 1.44)† 1.48 (1.32 to 1.66)*
Stroke 0.959 (4.1) 0.982 (1,8) 2.38 (2.01 to 2.80)* 1.86 (1.57 to 2.20)* 1.39 (1.08 to 1.79)† 1.27 (1.06 to 1.53)†
Heart failure 0.778 (22.2) 0.913 (8.7) 2.73 (2.55 to 2.94)* 2.1 (2.08 to 2.46)* 1.21 (1.09 to 1.35)* 1.29 (1.20 to 1.40)*
Bleeding 0.939 (6.1) 0.971 (2.9) 2.08 (1.81 to 2.38)* 1.72 (1.50 to 1.98)* 1.25 (1.01 to 1.56)† 1.26 (1.09 to 1.47)†
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, smoking and comorbidities (including previous PCI and CABG).
Model 3: adjusted for age, sex, smoking, comorbidities, guideline-based therapy (DAPT), ARB/ACEi, beta blockers and statins, and 
management with PCI and CABG.
*P<0.001.
†P<0.05.
ACEi, ACE inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy (aspirin and 
P2Y12 inhibitor); MACE, major adverse cardiac events; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary 
intervention.
dISCuSSIon
To the best of our knowledge, this is the largest registry 
study to date investigating the baseline and in-hos-
pital characteristics including procedures, discharge 
medication as well as 1-year MACE following MI in 
a population with established PAD. Our main find-
ings were significant associations between PAD and 
higher 1-year rates of MACE, mortality, reinfarc-
tion, stroke, heart failure and bleeding following MI. 
After adjustments for baseline differences including 
age, comorbidities and guideline-based secondary 
preventive medical therapies, the HR was lowered 
but independent statistically significant associations 
between PAD and higher occurrence of all endpoints 
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Figure 1 (A–F) Kaplan-Meier survival curves showing the crude 1-year estimates of MACE (mortality, reinfarction, stroke and 
heart failure), mortality, reinfarction, stroke, heart failure and bleeding rates in an MI population with and without PAD. MACE, 
major adverse cardiac events; MI, myocardial infarction; PAD, peripheral artery disease.
remained, indicating a high risk accompanied with 
PAD after MI.
Patient characteristics and clinical presentation
The prevalence of previously diagnosed PAD in the 
MI population was 3.8% in our study, which is lower 
than what previous studies have reported.4 5 8 9 Two 
other studies found the PAD prevalence to be 8.2% and 
13.5% in study populations of 28 771 and 4480 subjects, 
respectively, were relatively small-scaled compared with 
our study population (n=110 976). The highest prev-
alence of 40%8 and 42%9 were found in even smaller 
studies with 100 and 952 subjects correspondingly. The 
latter studies were the only studies that defined PAD 
by measuring the ankle–brachial index of the subjects 
in the clinical settings. The large differences between 
symptomatic PAD and PAD defined by screening with 
ankle–brachial index are likely explained by the rela-
tively long subclinical asymptomatic phase of PAD 
before the disease manifests itself clinically. A system-
atic review by Fowkes et al,12 pooling a total of 112 027 
participants, found the prevalence of PAD in the age 
range between 55 and 79 years to be roughly 9.5%. 
Taken together, the relatively low PAD prevalence in 
our study reflects symptomatic PAD that has led to a 
clinical diagnosis, which is vastly different from subclin-
ical PAD.
We found that patients with PAD had more cardiac 
risk factors, such as smoking, hypertension, hyper-
lipidaemia and diabetes, and were generally more 
comorbid, which is in accordance with previous 
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research.2 7 8 A slightly lower blood pressure was seen 
in the PAD population; however, since blood pressure 
was measured peripherally, there is a possibility of false 
low levels due to subclavian disease in this population. 
Patients with PAD had higher rates of previous PCI 
and CABG at baseline and higher rates of CABG but 
lesser rates of PCI during MI hospitalisation, indicating 
more advanced coronary heart disease. This is further 
corroborated by the angiographic findings with more 
multivessel and left main disease in the PAD popula-
tion. Our results are supported by a study that found 
PAD associated with more previous revascularisations.2 
Further supporting our study, results from the OPUS-
TIMI study showed that PAD patients more often had 
severe CAD and subsequently underwent more CABG 
compared with PCI.7
discharge medications
The PAD population was less likely to be treated with 
DAPT at discharge, but they were more often prescribed 
warfarin in line with an increased prevalence of atrial 
fibrillation. Newer studies have implicated that antithrom-
botic medications, such as ticagrelor and clopidogrel, 
could be advantageous as supplementing therapies in 
reducing the risk of cardiovascular events in patients with 
PAD.10 13 14 The COMPASS PAD trial10 concluded, for 
the first time, the use of rivaroxaban (2.5 mg two times 
per day) and aspirin as superior treatment compared 
with aspirin alone with reduced rates of adverse cardiac 
events. Another recent antithrombotic treatment alterna-
tive is prolonged treatment with low-dose ticagrelor (60 
mg two times per day), which has had promising results 
published with regard to MI patients with concomitant 
PAD.13 Yet again, these studies were published after our 
study period and thus, the indications were not approved 
during our study’s time frame.
endpoints
A prospective study by Grenon et al2 including 2018 
patients with stable CAD concluded an HR of 1.8 (95% 
CI 1.2 to 2.7) of death and an HR of 1.7 (95% CI 1.0 to 
2.9) for cardiovascular events for MI patients with PAD 
compared with MI patients without PAD. In our study, the 
corresponding HRs were 1.6 and 1.4, respectively. The 
difference is likely explained by the different definitions 
of cardiovascular events compared with our term MACE. 
Cardiovascular events in the mentioned study were 
defined as stroke, transient ischaemic attack, heart failure, 
MI, revascularisation and death. Furthermore, their 
adjustment model included race, self-reported history of 
PAD, inflammatory biomarkers, glycaemic control and 
health behaviours. Various other studies confirm the 
increased mortality seen in our study: a follow-up study 
by Dinser et al15 investigating 4307 patients with incident 
acute myocardial infarction (AMI) found the mortality 
HR (follow-up 5.7 years) to be 1.70 (95% CI 1.35 to 2.13) 
in the PAD population. Moreover, a study consisting of 
4480 patients hospitalised for AMI by Spencer et al5 found 
a 1-year mortality OR of 2.00 (95% CI 1.58 to 2.52).
The association between PAD and stroke has previ-
ously been described16 and our results corroborate this 
link, suggesting that the more arterial beds affected the 
more likely it is that an additional atherosclerotic vascular 
event will occur.
Patients with PAD had a higher risk of being hospital-
ised for heart failure following MI. In accordance with 
our results, a meta-analysis established PAD as an inde-
pendent predictor of adverse outcomes in patients with 
heart failure following MI.4 Both PAD and heart failure 
are associated with a high morbidity burden. As previously 
shown, patients with heart failure have a higher preva-
lence of PAD and present with worse clinical outcomes.17 
The treatment of PAD also includes exercise,18 which can 
present as a challenge in patients with heart failure due 
to decreased exercise capacity.19 Thus, this vulnerable 
population with three severe diagnoses, PAD, MI and 
heart failure, represent a particularly challenging clinical 
scenario.
A study by Baumann et al20 investigating the bleeding 
risk profile and HAS-BLED scores found that patients 
with PAD had higher risk of bleeding complications 
compared with the general population. We observed 
the same pattern in our population. Ischaemic risk and 
bleeding risk often increase in parallel, which our study 
also suggests is the case in PAD.
Clinical implication
MI patients with concomitant PAD are undoubtedly a 
high-risk population with a high prevalence of cardiac 
risk factors, challenging comorbidities and more severe 
CAD. There is an urgent need of a more interdisciplinary 
approach when dealing with this patient group. In the 
new guidelines of PAD management, it is pointed out 
that patients with CAD should be considered for PAD 
screening. After highlighting the various different PAD 
prevalences reported in our and others’ studies, we agree 
that PAD screening should be considered in selected 
patients with a high likelihood of subclinical PAD in 
order to diagnose the disease early, and subsequently 
optimally tailor the treatment and provide these patients 
with newer efficacious medical treatment alternatives.
limitations
All patients in our study have previously received an elec-
tronic code of PAD and this study, therefore, only entails 
those with a diagnosis of clinically manifested PAD. Some 
patients may have been excluded in the study due to 
various reasons relating to known limitations of regis-
try-based studies. These include, but are not limited to, 
subclinical disease and underdiagnosis, patients solely 
managed in the primary care setting and misclassifica-
tions of ICD diagnosis codes. Accordingly, we did not 
have data on the severity of PAD in the population as we 
had no information on ankle–brachial indexes or other 
PAD related measurements.
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ConCluSIon
In this contemporary nationwide population-based study, 
MI patients with concurrent PAD constituted a high-risk 
population that was independently and significantly asso-
ciated with higher risks of MACE, all-cause mortality, 
reinfarction, stroke, heart failure and bleeding after MI. 
These patients remain a challenging patient population 
and there is an urgent need of a more interdisciplinary 
approach to improve the management of these patients. 
Moreover, the prevalence of PAD in this study was low 
compared with previous research. Future studies should 
investigate if PAD screening with ankle–brachial index 
may combat underdiagnosing, which subsequently could 
lead to more patients being treated with novel efficacious 
treatments to alleviate the increased adverse outcomes of 
polyvascular disease.
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